Meta-analysis of clinical efficacy and safety of the treatment of impaired glucose tolerance by Tianqijiangtang Capsule

Objective： To evaluate the clinical efficacy and safety of Tianqijiangtang Capsule （TG） during the treatment ofimpaired glucose tolerance （IGT）. Methods： Using Chinese words of “impaired glucose tolerance, abnormalglucose tolerance, IGT” and “TG” as search terms, China National Knowledge Infrastructure, VIP, Wanfang Dataand Pubmed were searched from database inception until October 2017. All the controlled clinical researches on thetreatment of IGT by TG meeting the inclusion and exclusion criteria were retrieved and analyzed by ReviewManager 5.3 software. Results： A total of 7 articles including 1082 participants were enrolled. Meta-analysisshowed that the OR value of inversion rate was 2.17, 95% CI （1.65, 2.84）. Weighted mean difference （WMD） valueof fasting plasma glucose was -0.25, 95% CI （-0.39, -0.11）. After 2 h, the WMD value of serum glucose was -0.73,95% CI （-0.96, -0.51）, all of which were better than these of control group. The OR value of progression rate （type2 diabetes mellitus） was 0.44, 95% CI （0.32, 0.59）, less than the control group. All of the differences werestatistically significant. No hepatic and renal toxicity case was reported. Only 1 article reported adverse reactions inthe course of treatment. Conclusion： TG could treat IGT effectively, delay and even invert the progress of IGT, butits security still needed further discussion.

Effects of Dengzhan Shengmai Capsule combined with antiplatelet drug and statin therapy on platelet function, inflammatory response and lipid metabolism in patients with unstable angina pectoris

Objective: To study the effects of Dengzhan Shengmai Capsule combined with antiplatelet drug and statin therapy on platelet function, inflammatory response and lipid metabolism in patients with unstable angina pectoris. Methods: A total of 96 patients who were diagnosed with unstable angina pectoris for the first time in Beijing Shunyi District Hospital of Traditional Chinese Medicine between February 2015 and January 2018 were chosen and randomly divided into two groups, the observation group received Dengzhan Shengmai Capsule combined with antiplatelet drug and statin therapy, and the control group only accepted antiplatelet drug and statin therapy. Platelet function parameters, inflammatory response parameters and lipid metabolism parameters were determined before treatment and after 2 months of treatment. Results: Compared with those of same group before treatment, PAF, P-selectin, PDGF, E-selectin, Gal-3, TNF-α, IFN-γ, LDL-C, PCSK9, Chemerin and Visfatin contents in serum as well as C3aR and C5aR contents in peripheral blood platelets of both groups of patients were decreasing whereas sFGL2, TGF-β1, APN and Vaspin contents in serum were increasing after treatment, and PAF, P-selectin, PDGF, E-selectin, Gal-3, TNF-α, IFN-γ, LDL-C, PCSK9, Chemerin and Visfatin contents in serum as well as C3aR and C5aR contents in peripheral blood platelets of observation group after treatment were lower than those of control group whereas sFGL2, TGF-β1, APN and Vaspin contents in serum were higher than those of control group. Conclusion: Dengzhan Shengmai Capsule combined with antiplatelet drug and statin therapy for unstable angina pectoris can more effectively inhibit the platelet aggregation and improve the inflammatory response and lipid metabolism.

Kinematic improvement after the external-application herbs combine rehabilitation in upper-limb spasticity due to stroke

Background: Spasm is one of the most serious physical impairment after stroke. the external-application herbs have showed some effects on the spasm. This study was conducted to evaluate the comparative effectiveness of the external-application herbs and physical therapy in upper limb spasticity after stroke. Methods: A total of 100 patients with upper limb spasm after stroke (stroke time less than 1 month), have been recruited in Shun-yi Hospital of Beijing Traditional Chinese Medicine Hospital. Patients will be randomly allotted to one of two groups (N = 50, respectively): the TCM external application group, and the usual rehab (conventional physical therapy and medication treatment) group. The two groups will be administered once a month for three months. The primary outcome will be Modified Athworth Scale (MAS) and the simplified scale (Fugl-Meyer assessment, FMA) for upper limb. Results: Muscle tension and motor function were evaluated before and 4 weeks after treatments. There was a significant improvement in muscle tension and motor function in patients with stroke after the external-application herbs and physical therapy (P < 0.05). Conclusion: There was a significant improvement in kinematics in patients with stroke.

Efficacy of Modified Qufeng Runmian Powder(加减祛风润面散)on Acne Vulgaris with Syndromes of Dampness and Blood Stasis:A Multicenter,Randomized,Double-Blind,Placebo-Controlled Clinical Trial

Objective:To evaluate the efficacy and safety of a Chinese medicine(CM)Modified Qufeng Runmian Powder(加减祛风润面散,MQFRMP)for the treatment of acne vulgaris with CM syndromes of dampness and blood stasis.Methods:In this multicenter,randomized,double-blind,placebo-controlled clinical trial,220 acne vulgaris patients with CM syndrome of dampness and blood stasis were included and randomly assigned using a central area group random design to receive either MQFRMP or the placebo,with 110 cases in each group.MQFRMP or a placebo at 145 g/bag were administered once daily for 4 weeks,respectively.The primary index of efficacy was the effective rate according to the acne severity score(ASS).The secondary indices of efficacy included the changes in the dermatology life quality index(DLQI)score,VISIA scores(spots,pores,brown spots,porphyrins and red areas)and skin assessment(skin p H,sebum amount and hydration)according to a SOFT skin multianalyzer.Results:(1)Follow-up:a total of 204 patients completed the follow-up,with 103 in the treatment group and 101 in the control group.(2)Effective rate:the total effective rate of the treatment group was significantly higher than the control group[83.5%(86/103)vs.31.7%(32/101),P<0.01)]with 95%confidence interval of 39.3%–66.4%.(3)DLQI:DLQI scores were significantly decreased the treatment and control groups(both P<0.01),but the treatment group was more obvious than the placebo group(P<0.01).(4)VISIA scores:the scores of spots,brown spots and red areas in the treatment group decreased compared with baseline(P<0.05).In the control group,the scores of brown spots and pores decreased compared with baseline(P<0.05).The improvement was more obvious in the treatment group than in the control group for all items(P<0.05).(5)Skin assessment:the p H and sebum score in the both groups decreased drastically compared with the baseline(all P<0.01),however,the improvement was more obvious in the treatment group than in the control group(P<0.01).The hydration amount in the two groups showed no statistically significant difference compared with the baseline(both P>0.05).(6)Safety:two cases of mild drug allergy were observed in the treatment group.Conclusion:MQFRMP was effective and safe for the treatment of acne vulgaris with syndromes of dampness and blood stasis.(No.ChiCTR1900020479).